Sign inJoin waitlistJoin the waitlist

MA

Mark Awad

Chief, Thoracic Oncology Service · New York Presbyterian Hospital

Credentials: · · · · · ·

History

Thoracic Oncology Service Division · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Medical Oncology
2011–2013
Internal Medicine
Massachusetts General Hospital
2008–2011
Johns Hopkins School of Medicine
2004–2008

Research

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
New England Journal of Medicine · 2022 · 2,432 citations
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Cancer Discovery · 2018 · 1,415 citations
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
The Lancet Oncology · 2016 · 1,187 citations

Biagio Ricciuti
111 papers · 85 as a resident
Lynette Sholl
60 papers
Pasi Jänne
44 papers
Scott Rodig
30 papers
BJ
Bruce Johnson
27 papers
AS
Adam Schoenfeld
25 papers · 11 as a fellow
JG
Justin Gainor
25 papers · 4 as a fellow
MH
Matthew Hellmann
23 papers
Stephen Hodi
21 papers
AE
Arielle Elkrief
20 papers
John Heymach
20 papers
VV
Victor Vaz
19 papers · 17 as a resident

Grants

Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
National Cancer Institute · P50
Project lead · $686.3K · Dana-Farber Cancer Inst
2022–2027
Study of Plasma Next Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients with ALK Drug Resistance (SPACEWALK)
National Cancer Institute · R21
Contact PI · $191.9K · Dana-Farber Cancer Inst
2018–2021

Clinical trials

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2018–2021
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Principal investigator · Terminated · Phase 1, Phase 2
Dana-Farber Cancer Institute
2017–2019
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2017–2024
Merestinib In Non-Small Cell Lung Cancer And Solid Tumors
Principal investigator · Terminated · Phase 2
Dana-Farber Cancer Institute
2016–2023